Patents by Inventor Marc Ostermeier

Marc Ostermeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170369855
    Abstract: The present invention provides methods of systems and methods of site specific methylation.
    Type: Application
    Filed: December 24, 2015
    Publication date: December 28, 2017
    Inventors: Carl NOVINA, Glenna MEISTER, Marc OSTERMEIER, Tina XIONG
  • Publication number: 20170058268
    Abstract: The present invention provides an in vitro directed evolution selection system to create modified methyltransferases which improve methyltransferase specificity and use it to optimize and provide fusion proteins comprising a zinc finger methyltransferase derived from M.SssI. The resulting fusion proteins show increased target methylation specificity and greatly decreased non-target methylation compared to wild-type enzyme activity. Methods of use of such fusion proteins in both prokaryotic and eukaryotic cells are also provided.
    Type: Application
    Filed: March 11, 2015
    Publication date: March 2, 2017
    Inventors: Marc Ostermeier, Brian Chaikind
  • Patent number: 9469841
    Abstract: The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: October 18, 2016
    Assignee: The Johns Hopkins University
    Inventors: Marc A. Ostermeier, Chapman M. Wright
  • Patent number: 9273319
    Abstract: The invention provides molecular switches which couple external signals to functionality and to methods of making and using the same. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches and expression vectors and host cells for expressing the switches are also provided.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: March 1, 2016
    Assignee: The Johns Hopkins University
    Inventor: Marc Ostermeier
  • Publication number: 20140273217
    Abstract: The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 18, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Marc A. Ostermeier, Chapman M. Wright
  • Patent number: 8592192
    Abstract: A strategy to improve protein stability by domain insertion. TEM 1 beta-lactamase (BLA) and exo-inulinase, as model target enzymes, are inserted into a hyperthermophilic maltose binding protein from Pyrococcus furiosus (PfMBP). Unlike conventional protein stabilization methods that employ mutations and recombinations, the inventive approach does not require any modification on a target protein except for its connection with a hyperthermophilic protein scaffold. For that reason, target protein substrate specificity was largely maintained, which is often modified through conventional protein stabilization methods. The insertion was achieved through gene fusion by recombinant DNA techniques.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: November 26, 2013
    Assignee: Polytechnic Institute of NYU
    Inventors: Jin Ryoun Kim, Brennal Pierre, Marc Ostermeier, Chung-Sei Kim
  • Publication number: 20130230925
    Abstract: The invention provides molecular switches which couple external signals to functionality and to methods of making and using the same. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches and expression vectors and host cells for expressing the switches are also provided.
    Type: Application
    Filed: February 28, 2013
    Publication date: September 5, 2013
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventor: Marc Ostermeier
  • Patent number: 8492122
    Abstract: The invention provides molecular switches which couple external signals to functionality and to methods of making and using the same. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches and expression vectors and host cells for expressing the switches are also provided.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: July 23, 2013
    Assignee: The Johns Hopkins University
    Inventor: Marc Ostermeier
  • Patent number: 8338138
    Abstract: The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: December 25, 2012
    Assignee: The John Hopkins University
    Inventors: Marc A. Ostermeier, Gurkan Guntas
  • Patent number: 7820413
    Abstract: A series of methods that utilize the incremental truncation of nucleic acids are described to create a plurality of modified nucleic acids and hybrid polypeptides. A plurality of substantially all possible single base-pair deletions of a given nucleic acid sequence is created. A method of making shuffled incremental truncated nucleic acids, which is independent of nucleic acid sequence homology, is also described. These methods can be used in protein engineering, protein folding, protein evolution, and the chemical synthesis of novel hybrid proteins and polypeptides.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: October 26, 2010
    Assignee: The Penn State Research Foundation
    Inventors: Stephen J. Benkovic, Marc Ostermeier, Stefan Lutz, Andrew E. Nixon
  • Publication number: 20100227374
    Abstract: A strategy to improve protein stability by domain insertion. TEM 1 beta-lactamase (BLA) and exo-inulinase, as model target enzymes, are inserted into a hyperthermophilic maltose binding protein from Pyrococcus furiosus (PfMBP). Unlike conventional protein stabilization methods that employ mutations and recombinations, the inventive approach does not require any modification on a target protein except for its connection with a hyperthermophilic protein scaffold. For that reason, target protein substrate specificity was largely maintained, which is often modified through conventional protein stabilization methods.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 9, 2010
    Inventors: Jin Ryoun Kim, Brennal Pierre, Marc Ostermeier, Chung-Sei Kim
  • Publication number: 20090005266
    Abstract: The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.
    Type: Application
    Filed: January 28, 2005
    Publication date: January 1, 2009
    Applicant: The Johns Hopkins University
    Inventors: Marc A. Ostermeier, Gurkan Guntas
  • Publication number: 20080227650
    Abstract: A series of methods that utilize the incremental truncation of nucleic acids are described to create a plurality of modified nucleic acids and hybrid polypeptides. A plurality of substantially all possible single base-pair deletions of a given nucleic acid sequence is created. A method of making shuffled incremental truncated nucleic acids, which is independent of nucleic acid sequence homology, is also described. These methods can be used in protein engineering, protein folding, protein evolution, and the chemical synthesis of novel hybrid proteins and polypeptides.
    Type: Application
    Filed: February 19, 2008
    Publication date: September 18, 2008
    Inventors: Stephen J. Benkovic, Marc Ostermeier, Stefan Lutz, Andrew E. Nixon
  • Publication number: 20080227659
    Abstract: A series of methods that utilize the incremental truncation of nucleic acids are described to create a plurality of modified nucleic acids and hybrid polypeptides. A plurality of substantially all possible single base-pair deletions of a given nucleic acid sequence is created. A method of making shuffled incremental truncated nucleic acids, which is independent of nucleic acid sequence homology, is also described. These methods can be used in protein engineering, protein folding, protein evolution, and the chemical synthesis of novel hybrid proteins and polypeptides.
    Type: Application
    Filed: February 19, 2008
    Publication date: September 18, 2008
    Inventors: Stephen J. Benkovic, Marc Ostermeier, Stefan Lutz, Andrew E. Nixon
  • Patent number: 7332308
    Abstract: A series of methods that utilize the incremental truncation of nucleic acids are described to create a plurality of modified nucleic acids and hybrid polypeptides. A plurality of substantially all possible single base-pair deletions of a given nucleic acid sequence is created. A method of making shuffled incremental truncated nucleic acids, which is independent of nucleic acid sequence homology, is also described. These methods can be used in protein engineering, protein folding, protein evolution, and the chemical synthesis of novel hybrid proteins and polypeptides.
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: February 19, 2008
    Assignee: The Penn State Research Foundation
    Inventors: Stephen J. Benkovic, Marc Ostermeier, Stefan Lutz, Andrew E. Nixon
  • Patent number: 6027888
    Abstract: Disclosed are methods of producing eukaryotic disulfide bond-containing polypeptides in bacterial hosts, and compositions resulting therefrom. Co-expression of a eukaryotic foldase and a disulfide bond-containing polypeptide in a bacterial host cell is demonstrated. In particular embodiments, the methods have been used to produce mammalian pancreatic trypsin inhibitor and tissue plasminogen activator (tPA) in soluble, biologically-active forms, which are isolatable from the bacterial periplasm. Also disclosed are expression systems, recombinant vectors, and transformed host cells.
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: February 22, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: George Georgiou, Marc Ostermeier